<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="brief-report" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Our Dermatol Online</journal-id>
<journal-title>Our Dermatol Online</journal-title>
<issn pub-type="epub">2081-9390</issn>
<publisher>
<publisher-name>Our Dermatology Online</publisher-name>
<publisher-loc>Poland</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">OURD-8-264</article-id>
<article-id pub-id-type="doi">10.7241/ourd.20173.76</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Brief Report</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Childhood vitiligo: Clinical epidemiological profile</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Lahlou</surname>
<given-names>Asmae</given-names>
</name>
<xref ref-type="aff" rid="aff1"/>
<xref ref-type="corresp" rid="cor1"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Baybay</surname>
<given-names>Hanane</given-names>
</name>
<xref ref-type="aff" rid="aff1"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gallouj</surname>
<given-names>Salim</given-names>
</name>
<xref ref-type="aff" rid="aff1"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mernissi</surname>
<given-names>Fatima-Zohra</given-names>
</name>
<xref ref-type="aff" rid="aff1"/>
</contrib>
</contrib-group>
<aff id="aff1"><italic>Department of Dermatology, University Hospital Hasssan II, Fez, Morocco</italic></aff>
<author-notes>
<corresp id="cor1">
<bold>Corresponding author:</bold> Dr. Asmae Lahlou, E-mail: <email xlink:href="lahlouasmae@gmail.com">lahlouasmae@gmail.com</email>
</corresp>
</author-notes>
<pub-date pub-type="ppub">
<year>2017</year>
</pub-date>
<volume>8</volume>
<issue>3</issue>
<fpage>264</fpage>
<lpage>267</lpage>
<history>
<date date-type="received"><day>19</day><month>09</month><year>2016</year></date>
<date date-type="accepted"><day>17</day><month>05</month><year>2017</year></date>
</history>
<permissions>
<copyright-statement>Copyright: &#x000a9; Our Dermatol Online 3</copyright-statement>
<copyright-year>2017</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p>
</license>
</permissions>
<abstract>
<sec id="st1">
<title>Objective:</title>
<p>To study the clinical and the epidemiologic profiles of childhood vitiligo.</p>
</sec>
<sec id="st2">
<title>Patients and Methods:</title>
<p>We prospectively analyzed the clinical data of children with vitiligo presented to the dermatology derpartement at University Hospital &#x2013; F&#x00E8;s for 5 years from May 2011 to May 2016. This study included 31 patients. All patients were assessed for the natural history, clinical characteristics, family history, and associated abnormalities of vitiligo.</p>
</sec>
<sec id="st3">
<title>Results:</title>
<p>Of the 31 children with vitiligo 9 (29,03&#x0025;) were boys and 21 (67.74&#x0025;) were girls. The mean age of onset of the vitiligo was 10 years. The mean duration of the disease was 38,9 weeks. The most common type of vitiligo was vitiligo vulgaris (49.5&#x0025;) followed by focal vitiligo (39&#x0025;), acrofacial vitiligo (32&#x0025;), and segmental vitiligo (16&#x0025;) The most frequent site of onset was the extremities followed by the head and the neck, then the trunk and the genitalia. Of the 31 children with vitiligo, 39&#x0025; had a family history and 4 &#x0025; had an antecedent of autoimmune diesease like le diab&#x00E8;te, une thyro&#x00EF;dite, l&#x2019;an&#x00E9;mie et le psoriasis, retrouv&#x00E9;.</p>
</sec>
<sec id="st4">
<title>Conclusion:</title>
<p>Our children have a strong family history of vitiligo and they are developing the disease at a slightly older age compared with those of other studies; however, other epidemiologic features appear to be similar to those reported in the previously published studies.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Keys words: Vitiligo</kwd>
<kwd>Childhood</kwd>
<kwd>Depigmentation</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-1" sec-type="intro">
<title>INTRODUCTION</title>
<p>Vitiligo is an acquired, sometimes familial depigmentary disorder of the skin and hair which results from selective destruction of melanocytes. The prevalence of vitiligo ranges from 0.1&#x0025; to 2&#x0025; in various populations, The exact prevalence in the pediatric population is unknown, vitiligo begins before the age of ten years in about 25&#x0025; of cases [<xref ref-type="bibr" rid="ref1">1</xref>]. The average age in different studies ranges from four to eight years with a very early start possible from the age of three months [<xref ref-type="bibr" rid="ref2">2</xref>-<xref ref-type="bibr" rid="ref3">3</xref>]. Vitiligo in childhood can be associated with significant psychological trauma that may have long-lasting effects on the self-esteem of these children.</p>
<p>The existence of congenital forms is controversial [<xref ref-type="bibr" rid="ref4">4</xref>]. In individuals with fair skin, vitiligo is usually visible after a first sun exposure that will accentuate the contrast with healthy skin. a predominance of girls is noted in all pediatric series [<xref ref-type="bibr" rid="ref3">3</xref>,<xref ref-type="bibr" rid="ref5">5</xref>-<xref ref-type="bibr" rid="ref7">7</xref>]. If all races can be affected, it would seem that the prevalence of child vitiligo is higher in India, but it could be secondary to increased social attention [<xref ref-type="bibr" rid="ref8">8</xref>]. the objective of this work is to study the clinical and the epidemiologic profiles of childhood vitiligo through the analysis of a series of 31 cases of children with vitiligo.</p>
</sec>
<sec id="sec1-2" sec-type="materials|methods">
<title>MATERIALS AND METHODS</title>
<p>A retrospective analysis was made on records of the patients attending the dermatology derpartement at University Hospital&#x2013; Fes during 5 years from May 2011 to May 2016. All patients &#x2264;17 years of age with vitiligo referred to the clinic were included in this study. Demographic details of all patients including the age of onset, initial site of onset, duration of disease, associated mucosal involvement, associated diseases, and family history were obtained from the clinic notes.</p>
</sec>
<sec id="sec1-3" sec-type="results">
<title>RESULTS</title>
<p>Of the total 31 children with vitiligo in the present study 9 (29,03&#x0025;) were boys and 21 (67.74&#x0025;) were girls. The age of onset of vitiligo ranged from 3 mounth to 17 years (mean 10 years). The mean duration of disease was 38,9 weeks. Vitiligo affecting first and second-degree relatives was reported by 12 (39&#x0025;) patients including 8 girls (66,6&#x0025;) and 4 boys (33,3&#x0025;). The triggering factor was found in 20&#x0025; of cases following a psycho-trauma, the affected area was variable up to 40&#x0025; in extended forms. The most common clinical type of vitiligo seen in our patients is vitiligo vulgaris (94.5&#x0025;), followed by focal vitiligo (39&#x0025;), acrofacial vitiligo (32&#x0025;), and segmental vitiligo (32&#x0025;), in that order (<xref ref-type="fig" rid="F1">Fig. 1</xref>). The most common site of onset was the extremities (45&#x0025;), the trunk (35&#x0025;), followed by the head and the neck area (32&#x0025;), and the genitalia (2&#x0025;) (<xref ref-type="fig" rid="F2">Fig. 2</xref>). five children had associated abnormalities. 4 patients atopic eczema, one had positive anti-thyroid antibodies but no showed a clinical evidence of thyroid diseaseLaboratory tests had not shown diabetes, or autoimmune anemia in other patients, the proposed treatment was topical corticosteroids in 13&#x0025; of cases, protopic in 61.2&#x0025; of cases and in 22 UVB HTL01, 5&#x0025; of cases, with good evolution in 42&#x0025; and unsatisfactory progress in 58&#x0025; of cases.</p>
<fig id="F1">
<label>Figure 1</label>
<caption>
<p>Vitiligo on the back in a child of 5 years old.</p>
</caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="OURD-8-264-g001.tif"/>
</fig>
<fig id="F2">
<label>Figure 2</label>
<caption>
<p>Vitiligo perished orificiel back in a child of 3 years old.</p>
</caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="OURD-8-264-g002.tif"/>
</fig>
</sec>
<sec id="sec1-4" sec-type="discussion">
<title>DISCUSSION</title>
<p>Many studies state that most vitiligo is primarily acquired early in life, We have attempted to compare our findings with those in the previous studies from different countries, a comparison of the patterns of vitiligo and its associated disorders in different studies, including ours, is represented in <xref ref-type="table" rid="T1">Table 1</xref>.</p>
<table-wrap id="T1">
<label>Table 1</label>
<caption>
<p>Comparison of patterns of vitiligo and observed associated disorders between different studies, including our study</p>
</caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="OURD-8-264-g003.tif"/>
</table-wrap>
<p>The mean age of onset in the pediatric age group has been found to be 4.6 years in an American study [<xref ref-type="bibr" rid="ref6">6</xref>], 5.6 years in a Korean study [<xref ref-type="bibr" rid="ref2">2</xref>] 6.2 years in Kuwaiti study [<xref ref-type="bibr" rid="ref9">9</xref>].</p>
<p>Our results reveal that the mean age of onset was 7.9 years, which mean that our patients develop vitiligo in a slightly older age than in others. The exact reasons for this are unclear. Our review show a preponderance of girls in children with vitiligo, similar to the observation made in majority of previously reported studies [<xref ref-type="bibr" rid="ref6">6</xref>-<xref ref-type="bibr" rid="ref9">9</xref>,<xref ref-type="bibr" rid="ref10">10</xref>]. Although, two studies from Korea and China noted an almost equal incidence in boys and girls [<xref ref-type="bibr" rid="ref2">2</xref>,<xref ref-type="bibr" rid="ref11">11</xref>,<xref ref-type="bibr" rid="ref12">12</xref>].</p>
<p>The observed female predominance can be explained by their emotional fragility and the most major cosmetic concern of parents that is the case in our context.</p>
<p>Approximately 39&#x0025; of patients in our study had a family history of vitiligo We believe that genetic factors play a role herein, as there is a high incidence of consanguineous marriage in our country.</p>
<p>Similar to our finding Halder et al. focal vitiligo was the second most common presentation. However, Jaisankar et al., in their study with 90 children, they reported segmental vitiligo as the second most frequent presentation, occurring in 21&#x0025; of patients, closely followed by focal vitiligo in 20.1&#x0025;. The percentage of segmental vitiligo has been reported to vary from 19&#x0025; to 21&#x0025; in children [<xref ref-type="bibr" rid="ref9">9</xref>,<xref ref-type="bibr" rid="ref10">10</xref>].</p>
<p>The extremities were the most common sites of onset in children in our series (45&#x0025;), that differe from other studies or that different from other studies or location of head and neck is the most common [<xref ref-type="bibr" rid="ref2">2</xref>,<xref ref-type="bibr" rid="ref5">5</xref>,<xref ref-type="bibr" rid="ref9">9</xref>,<xref ref-type="bibr" rid="ref10">10</xref>]. The association of vitiligo with other diseases/abnormalities has also been a subject of great interest.</p>
<p>In earlier published reports on childhood vitiligo, vitiligo vulgaris was the most frequent type reported [<xref ref-type="bibr" rid="ref9">9</xref>,<xref ref-type="bibr" rid="ref10">10</xref>]. In our study as well, this is the most common clinical type seen in 94,5&#x0025;.</p>
<p>A previous study reported that four children of 33 (12.1&#x0025;) screened had antithyroid antibodies, although they were all clinically asymptomatic [<xref ref-type="bibr" rid="ref9">9</xref>]. This is consistent with our finding of antithyroid antibodies in 2,33 &#x0025; all of them were clinically asymptomatic.</p>
<p>In our study 1 of 31 children (3,22&#x0025;) had associated autoimmune disease namely, alopecia areata. This is consistent with Halder et al. study as they reported two cases of alopecia areata in 82 children (2.4&#x0025;) with vitiligo. One study from Kuwait found 1.1&#x0025; of children with vitiligo had alopecia areata [<xref ref-type="bibr" rid="ref9">9</xref>].</p>
<p>In a study from North India, 1.3&#x0025; of children (8 of 625 children) had an associated autoimmune disease including alopecia areata, diabetes mellitus, thyroid disease, Addison&#x2019;s disease, polyglandular syndrome or pemphigus vulgaris [<xref ref-type="bibr" rid="ref5">5</xref>].</p>
<p>In addition, two studies have reported an increased prevalence of various autoantibodies in patients with vitiligo [<xref ref-type="bibr" rid="ref12">12</xref>,<xref ref-type="bibr" rid="ref13">13</xref>]. A recent article has reported the presence of thyromegaly, antithyroid antibodies and thyroid dysfunction in significant numbers of children and adolescents with vitiligo [<xref ref-type="bibr" rid="ref14">14</xref>,<xref ref-type="bibr" rid="ref15">15</xref>].</p>
</sec>
<sec id="sec1-5" sec-type="conclusion">
<title>CONCLUSION</title>
<p>We observe that children in our study have a strong family history of vitiligo than other population and are developing the disease at a slightly older age compared with other studies; however, other epidemiologic features appear to be similar to those reported in the previously published studies.</p>
</sec>
</body>
<back>
<ref-list>
<title>REFERENCES</title>
<ref id="ref1">
<label>1</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Howitz</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Brodthagen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Thomsen</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Prevalence of vitiligo. Epidemiological survey of the Isle of Bornholm, Denmark</article-title>
<source>Arch Dermatol</source>
<year>1997</year>
<volume>113</volume>
<fpage>47</fpage>
<lpage>52</lpage>
</nlm-citation>
</ref>
<ref id="ref2">
<label>2</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cho</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Hahm</surname>
<given-names>JH</given-names>
</name>
</person-group>
<article-title>Characteristics of vitiligo in Korean children</article-title>
<source>Pediatr Dermatol</source>
<year>2000</year>
<volume>17</volume>
<fpage>189</fpage>
<lpage>93</lpage>
</nlm-citation>
</ref>
<ref id="ref3">
<label>3</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pr&#180;ci&#180;c</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Duran</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Poljacki</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Vitiligo in childhood</article-title>
<source>Med Pregl</source>
<year>2002</year>
<volume>55</volume>
<fpage>475</fpage>
<lpage>80</lpage>
</nlm-citation>
</ref>
<ref id="ref4">
<label>4</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nordlund</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Lerner</surname>
<given-names>AB</given-names>
</name>
</person-group>
<article-title>Vitiligo</article-title>
<source>It is important. Arch Dermatol</source>
<year>1982</year>
<volume>118</volume>
<fpage>5</fpage>
<lpage>8</lpage>
</nlm-citation>
</ref>
<ref id="ref5">
<label>5</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Handa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dogra</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Epidemiology of childhood vitiligo:a study of 625 patients from North India</article-title>
<source>Pediatr Dermatol</source>
<year>2003</year>
<volume>20</volume>
<fpage>207</fpage>
<lpage>10</lpage>
</nlm-citation>
</ref>
<ref id="ref6">
<label>6</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Halder</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Grimes</surname>
<given-names>PE</given-names>
</name>
<name>
<surname>Cowan</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Enterline</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Chakrabarti</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Kenney</surname>
<given-names>JA</given-names>
<suffix>Jr</suffix>
</name>
</person-group>
<article-title>Childhood vitiligo</article-title>
<source>J Am Acad Dermatol</source>
<year>1987</year>
<volume>16</volume>
<fpage>948</fpage>
<lpage>54</lpage>
</nlm-citation>
</ref>
<ref id="ref7">
<label>7</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mazereeuw-Hautier</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bezio</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mahe</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bodemer</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Eschard</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Viseux</surname>
<given-names>V</given-names>
</name>
<etal/>
</person-group>
<article-title>Groupe de recherche clinique en dermatologie p&#233;diatrique (GRCDP). Segmental and nonsegmental childhood vitiligo has distinct clinical characteristics:a prospective observational study</article-title>
<source>J Am Acad Dermatol</source>
<year>2010</year>
<volume>62</volume>
<fpage>945</fpage>
<lpage>9</lpage>
</nlm-citation>
</ref>
<ref id="ref8">
<label>8</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Handa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kaur</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Vitiligo:clinical findings in 1436 patients</article-title>
<source>J Dermatol</source>
<year>1999</year>
<volume>26</volume>
<fpage>653</fpage>
<lpage>7</lpage>
</nlm-citation>
</ref>
<ref id="ref9">
<label>9</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Halder</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Grimes</surname>
<given-names>PE</given-names>
</name>
<name>
<surname>Cowan</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Enterline</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Chakrabarti</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Kenney</surname>
<given-names>JA</given-names>
<suffix>Jr</suffix>
</name>
</person-group>
<article-title>Childhood vitiligo</article-title>
<source>J Am Acad Dermatol</source>
<year>1987</year>
<volume>16</volume>
<fpage>948</fpage>
<lpage>54</lpage>
</nlm-citation>
</ref>
<ref id="ref10">
<label>10</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Mutairi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Al-Sheltawy</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nour-Eldin</surname>
<given-names>O</given-names>
</name>
</person-group>
<article-title>Childhood vitiligo:a prospective hospital-based study</article-title>
<source>Australas J Dermatol</source>
<year>2005</year>
<volume>46</volume>
<fpage>150</fpage>
<lpage>3</lpage>
</nlm-citation>
</ref>
<ref id="ref11">
<label>11</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>XJ</given-names>
</name>
</person-group>
<article-title>Profile of childhood vitiligo in China:an analysis of 541 patients</article-title>
<source>Pediatr Dermatol</source>
<year>2006</year>
<volume>23</volume>
<fpage>114</fpage>
<lpage>6</lpage>
</nlm-citation>
</ref>
<ref id="ref12">
<label>12</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jaisankar</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Baruah</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Garg</surname>
<given-names>BR</given-names>
</name>
</person-group>
<article-title>Vitiligo in children</article-title>
<source>Int J Dermatol</source>
<year>1992</year>
<volume>31</volume>
<fpage>621</fpage>
<lpage>3</lpage>
</nlm-citation>
</ref>
<ref id="ref13">
<label>13</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Betterle</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Caretto</surname>
<given-names>A</given-names>
</name>
<name>
<surname>De</surname>
<given-names>Zio A</given-names>
</name>
<name>
<surname>Pedini</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Veller-Fornasa</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cecchetto</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Accordi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Peserico</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Incidence and significance of organ-specific autoimmune disorders (clinical, latent, or only autoantibodies) in patients with vitiligo</article-title>
<source>Dermatologica</source>
<year>1985</year>
<volume>171</volume>
<fpage>419</fpage>
<lpage>23</lpage>
</nlm-citation>
</ref>
<ref id="ref14">
<label>14</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naughton</surname>
<given-names>GK</given-names>
</name>
<name>
<surname>Reggiado</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bystryn</surname>
<given-names>JC</given-names>
</name>
</person-group>
<article-title>Correlation between vitiligo antibodies and extent of depigmentation in vitiligo</article-title>
<source>J Am Acad Dermatol</source>
<year>1986</year>
<volume>15</volume>
<fpage>978</fpage>
<lpage>81</lpage>
</nlm-citation>
</ref>
<ref id="ref15">
<label>15</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kurtev</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dourmishev</surname>
<given-names>AL</given-names>
</name>
</person-group>
<article-title>Thyroid function and autoimmunity in children and adolescents with vitiligo</article-title>
<source>J Eur Acad Dermatol Venerol</source>
<year>2004</year>
<volume>18</volume>
<fpage>99</fpage>
<lpage>117</lpage>
</nlm-citation>
</ref>
</ref-list>
<fn-group>
<fn fn-type="supported-by">
<p><bold>Source of Support:</bold> Nil</p>
</fn>
<fn fn-type="conflict">
<p><bold>Conflict of Interest:</bold> None declared.</p>
</fn>
</fn-group>
</back>
</article>